Chemotherapy in Invasive Carcinoma of the Bladder A review of phase II trials in Egypt
Open Access
- 1 January 1989
- journal article
- research article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 28 (1) , 73-76
- https://doi.org/10.3109/02841868909111185
Abstract
Since 1976, a series of phase II studies with screening of various chemotherapeutic agents in invasive bladder cancer have been conducted at the National Cancer Institute, Cairo. Different drugs were screened, one by one, in groups of 20-25 patients with inoperable, metastatic, or recurrent carcinomas. Evaluation was done by clinical bimanual examination, radiography, sonography, cystoscopy, and urine cytology. In these trials bleomycin and doxorubicin were ineffective. Tenoposide, 5-fluorouracil, methotrexate, and cisplatin had minimal or moderate effect (response rates 4-16%). More pronounced effect was found for dibromodulcitol, cyclophosphamide, pentamethylmelamine, etoposide, hexamethylmelamine, ifosfamide, vindesine, vincristine, and epidoxorubicin (response rates 18-60%). Some complete responders remained in response for a period of 3-7 years. Drugs seemed to be more effective in metastatic than in local lesions.Keywords
This publication has 2 references indexed in Scilit:
- Cancer of the Bilharzial bladderUrological Research, 1978
- Single-Drug Chemotherapy of Bladder Cancer with Adriamycin, VM-26 or BleomycinEuropean Urology, 1976